Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 29M | 10.3% |
| Gross Profit | 19M | 0.8% |
| Cost of Revenue | 11M | 37.1% |
| Operating expense | 27M | 16.8% |
| Net Income | -16M | 24.4% |
| EBITDA | -8M | 39.3% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 274M | 4.4% |
| Total Liabilities | 180M | 1.5% |
| Total Equity | 93M | 14% |
| Shares Outstanding | 96M | 0.3% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 19M | 252.3% |
| Cash from investing | -6.9M | 136.5% |
| Cash from financing | -69,000 | 37.8% |
EPS
Financial Highlights for Assertio Therapeutics in Q2 '25
Assertio Therapeutics reported a revenue of 29M, which is a 10.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 19M, marking a -0.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 11M, a 37.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 27M, showing a -16.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -16M, showing a -24.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -8M, showing a 39.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Assertio Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
